genuine question about dose escalation that I am slightly embarrassed to ask
Slightly embarrassed to be asking this, but: genuine question about dose escalation that I am slightly embarrassed to ask.
The early fullness profile felt different rather than worse. Hard to describe and impossible to quantify, so take it as an impression.
Watched heart rate on a wearable across twelve weeks because the threads said to. It moved a little and I have no idea whether that means anything.
The thing that surprised me was how much of the discussion here is inference rather than measurement.
Please do not ask me what dose you should be on. I genuinely do not know and neither does anyone else here.
best — the order this archive was captured in
It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it.
Kept a log specifically because there is so little published. It is one person and it is not data.
not approved anywhere, which is the single most important fact in this board
heart rate is the thing people report watching
wait for phase 3 before you argue about rankings
not approved anywhere, which is the single most important fact in this board
This is the sentence the rest of the board should read first. Phase 2 is not a label.
Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use, and that is a statement of fact rather than a disclaimer.
How fast was the escalation? That is usually the variable that explains the reports.
Read the phase 2 paper twice before ordering anything. Recommend that to anyone in this board: the error bars are the interesting part.
the glucagon component is why the metabolic story reads differently
Right, and it bears repeating that nothing here is approved anywhere and research material is not for human use.